A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Capecitabine on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Capecitabine on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2008

At a glance

  • Drugs Capecitabine; Ispinesib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jun 2008 Results announced in a Cytokinetics media release (9090632).
    • 30 Jun 2008 Status changed from in progress to completed, as reported by Cytokinetics.
    • 29 Apr 2008 Cytokinetics has reported that final results are expected to be available in the second half of 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top